Smith, B. D., Kasamon, Y. L., Kowalski, J., Gocke, C., Murphy, K., Miller, C. B., . . . Levitsky, H. I. (2010). K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate.
シカゴスタイル引用形Smith, B. Douglas, et al. K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients With Residual Disease On Imatinib Mesylate. 2010.
MLA引用形式Smith, B. Douglas, et al. K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients With Residual Disease On Imatinib Mesylate. 2010.
警告: この引用は必ずしも正確ではありません.